Clinical trials: Discrete Choice Experiment
Type II Diabetes
Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment
In 2012, the FDA Center for Devices and Radiological Health (CDRH) issued guidance to clarify the principal benefit-risk factors FDA considers during the reviews for premarket approval applications and de novo classification…
- Trial name
- NCT02637622
- Testing
- Best-Worst Scaling (Case 2), Discrete Choice Experiment
- Where
- United States
- Volunteers
- 1,103 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health